Golden has been acquired by ComplyAdvantage.Read about it here ⟶

List of Vaximm patents

List of Vaximm patents

List of The Siemon Company patents

List of Haemonetics patents

List of Sonic Solutions patents

List of companies in Kyle Harrison's investment portfolio

List of SBIR/STTR awards granted to Advanced Technology And Research Corporation

Patents where

Current Assignee

Name

is

Vaximm

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10980868 VEGFR-2 targeting immunotherapy approach	Patent 10980868 was granted and assigned to Vaximm on April, 2021 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	10980868	April 20, 2021
	‌ US Patent 10293037 DNA vaccine for use in pancreatic cancer patients	Patent 10293037 was granted and assigned to Vaximm on May, 2019 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	10293037	May 21, 2019
	‌ US Patent 9415098 DNA vaccine for use in pancreatic cancer patients	Patent 9415098 was granted and assigned to Vaximm on August, 2016 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	9415098	August 16, 2016
	‌ US Patent 9920297 None	Patent 9920297 was granted and assigned to Vaximm on March, 2018 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	9920297	March 20, 2018
	‌ US Patent 11357842 PD-L1 targeting DNA vaccine for cancer immunotherapy	Patent 11357842 was granted and assigned to Vaximm on June, 2022 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	11357842	June 14, 2022
	‌ US Patent 10815455 Salmonella-based vectors for cancer immunotherapy targeting Wilms' tumor gene WT1		Vaximm	Vaximm		United States Patent and Trademark Office	10815455	October 27, 2020
	‌ US Patent 10905752 VEGFR-2 targeting DNA vaccine for combination therapy	Patent 10905752 was granted and assigned to Vaximm on February, 2021 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	10905752	February 2, 2021
	‌ US Patent 10821163 Process for the production of a DNA vaccine for cancer immunotherapy	Patent 10821163 was granted and assigned to Vaximm on November, 2020 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	10821163	November 3, 2020
	‌ US Patent 9493738 Method for producing high yield attenuated	Patent 9493738 was granted and assigned to Vaximm on November, 2016 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	9493738	November 15, 2016
	‌ US Patent 10441645 MSLN targeting DNA vaccine for cancer immunotherapy	Patent 10441645 was granted and assigned to Vaximm on October, 2019 by the United States Patent and Trademark Office.	Vaximm	Vaximm		United States Patent and Trademark Office	10441645	October 15, 2019

10 results

0 selected

10 results

0 selected